Regenerative medicine

Amniowrap2™ Product Launch Leads Year of Highlights for BioStem Technologies

Retrieved on: 
Tuesday, January 30, 2024

POMPANO BEACH, Fla., Jan. 30, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived allografts for advanced wound care, today highlights its 2023 accomplishments and provides a business update.

Key Points: 
  • BioStem Technologies CEO, Jason Matuszewski, said, “2023 was a year of tremendous growth, progress and achievement for BioStem.
  • This growth is primarily attributed to the successful launch of Amniowrap2™, our innovative placental-derived allograft product designed to address a broad spectrum of wound applications.
  • BioStem Technologies appointed a proven life science sales leader, Mr. Shawn McCarrey, as Chief Commercial Officer.
  • BioStem will host a conference call and webcast to discuss fourth quarter and full year 2023 financial results in March 2024.

Muscular Dystrophy Association Announces Recipient of 2024 MDA Legacy Award for Achievement in Research, is Jeffrey Chamberlain, Ph.D., Leading Professor in Gene Therapy

Retrieved on: 
Tuesday, January 30, 2024

The award will be presented at the 2024 MDA Clinical & Scientific Conference on Monday, March 4, by Louis Kunkel, PhD , of Boston Children’s Hospital.

Key Points: 
  • The award will be presented at the 2024 MDA Clinical & Scientific Conference on Monday, March 4, by Louis Kunkel, PhD , of Boston Children’s Hospital.
  • The MDA Legacy Award for Achievement in Research is an annual recognition for outstanding accomplishments in neuromuscular disease research.
  • "The Muscular Dystrophy Association is elated to celebrate Dr. Chamberlain and honor him with the 2024 MDA Legacy Award for Achievement in Research for his achievements in translational research.
  • The previous recipient of the MDA Legacy Award for Achievement in Research in 2023 was Merit Cudkowicz, MD, MSC Massachusetts General Hospital, for her achievements in clinical research.

Pvolve Expands Leadership Team Following Year of Exponential Growth

Retrieved on: 
Wednesday, January 31, 2024

This leadership extension closely follows other recent announcements, including record-breaking franchise success and the Healthy Aging Study, supporting the brand’s growth and efficacious method.

Key Points: 
  • This leadership extension closely follows other recent announcements, including record-breaking franchise success and the Healthy Aging Study, supporting the brand’s growth and efficacious method.
  • “At Pvolve, our success is all about the dedication of our fantastic leadership and team," said Rachel Katzman, Founder of Pvolve.
  • The Pvolve team was awarded 28 franchise licenses in 2023, increasing their total number of franchise locations to 40.
  • For more information about the Pvolve Method, clinical research, and its franchise business, please visit https://www.pvolve.com/ .

RION Announces Initiation of Phase 2A Clinical Study for Purified Exosome Product™ (PEP™) in Diabetic Foot Ulcers

Retrieved on: 
Tuesday, January 30, 2024

RION, a clinical-stage regenerative medicine company, at the forefront of the exosome therapeutic revolution, has officially commenced a Phase 2A study aimed at assessing the efficacy and safety of its exclusive exosome regenerative therapeutic, known as Purified Exosome Product™ (PEP™), for the management of Diabetic Foot Ulcers (DFU).

Key Points: 
  • RION, a clinical-stage regenerative medicine company, at the forefront of the exosome therapeutic revolution, has officially commenced a Phase 2A study aimed at assessing the efficacy and safety of its exclusive exosome regenerative therapeutic, known as Purified Exosome Product™ (PEP™), for the management of Diabetic Foot Ulcers (DFU).
  • (Photo: Business Wire)
    Diabetic Foot Ulcers affect approximately 18.6 million people worldwide each year1 and are associated with increasing rates of amputation and death​​.
  • Building on the success of the Phase 1B study conducted at Mayo Clinic, RION's Phase 2A trial represents a significant step forward in the development of a regenerative biologic for Diabetic Foot Ulcers.
  • Not only will this study address a critical unmet need in chronic wound care, but it’s a pivotal moment for RION.

NABR Files Expanded Petition Challenging the Listing of Long-Tailed Macaques by the IUCN

Retrieved on: 
Thursday, February 1, 2024

On October 12, 2023, the IUCN Standards and Petitions Committee accepted NABR's initial petition challenging the IUCN's 2022 designation of long-tailed macaques as "endangered.

Key Points: 
  • On October 12, 2023, the IUCN Standards and Petitions Committee accepted NABR's initial petition challenging the IUCN's 2022 designation of long-tailed macaques as "endangered.
  • " NABR's initial petition, filed with the IUCN on September 11, 2023, concluded that the underlying scientific justification for the Endangered listing is "biased" and "not based upon the best available scientific information."
  • Prior to July 2022, long-tailed macaques were designated as "vulnerable" by the IUCN.
  • The submission of NABR's expanded petition initiates a formal process with the IUCN Standards and Petitions Committee to review available scientific information concerning the species' status under IUCN protocols.

NABR Files Expanded Petition Challenging the Listing of Long-Tailed Macaques by the IUCN

Retrieved on: 
Thursday, February 1, 2024

NABR's IUCN petition and the American Journal of Primatology article show long-tailed macaques are not endangered.

Key Points: 
  • NABR's IUCN petition and the American Journal of Primatology article show long-tailed macaques are not endangered.
  • On October 12, 2023, the IUCN Standards and Petitions Committee accepted NABR's initial petition challenging the IUCN's 2022 designation of long-tailed macaques as "endangered.
  • " NABR's initial petition, filed with the IUCN on September 11, 2023, concluded that the underlying scientific justification for the Endangered listing is "biased" and "not based upon the best available scientific information."
  • The submission of NABR's expanded petition initiates a formal process with the IUCN Standards and Petitions Committee to review available scientific information concerning the species' status under IUCN protocols.

ALS Network Welcomes New President and CEO

Retrieved on: 
Thursday, February 1, 2024

LOS ANGELES, Feb. 1, 2024 /PRNewswire/ -- The ALS Network, formerly ALS Golden West, welcomes Sheri Strahl, MPH, MBA, as its new president and CEO effective today, February 1, 2024. 

Key Points: 
  • LOS ANGELES, Feb. 1, 2024 /PRNewswire/ -- The ALS Network, formerly ALS Golden West, welcomes Sheri Strahl, MPH, MBA, as its new president and CEO effective today, February 1, 2024.
  • "Sheri is that rare leader with a mix of compassion and a drive for excellence," Patricia Schimbor, Esq., ALS Network Board Chair said.
  • As COO, she played a pivotal role in leading the organization to the milestone moment by shepherding both structural and legal changes from the ALS Association Golden West Chapter to the ALS Network.
  • As the organization's first president and CEO with a public health background, Strahl's dynamic, servant-leadership approach reflects how the ALS Network engages the ALS community - through meaningful connections to urgently advance three mission pillars of work in care, research, and advocacy.

Dr. Gail K. Naughton, Ph.D., MBA, World Renowned Authority and Pioneer in Regenerative Medicine Named Science Advisor and to Board of Directors of Michal Morrison Inc.

Retrieved on: 
Thursday, February 1, 2024

βSTEM6 is the result of two decades of research in regenerative medicine and recent advances in stem cell science.

Key Points: 
  • βSTEM6 is the result of two decades of research in regenerative medicine and recent advances in stem cell science.
  • Dr. Naughton, a global leader in regenerative medicine for the past 35 years, has successfully developed significant cell-based therapeutics and bioengineered tissue technologies throughout her career.
  • "I am honored to join the scientists and the board at Michal Morrison Inc.
  • Michal Morrison Inc. has been honored by the beauty industry for its innovative technology and exquisite brand design.

LifeSprout Enters into Licensing Agreement with Boyang Trading to Develop and Commercialize Next-Generation Lumina™ Dermal Filler in Greater China

Retrieved on: 
Wednesday, January 31, 2024

BALTIMORE, Jan. 31, 2024 /PRNewswire/ -- LifeSprout, a privately held regenerative medicine company founded with technology licensed from Johns Hopkins University, today announced it has entered into a definitive agreement with Boyang Trading Co., Ltd. to exclusively develop and commercialize the Lumina™ dermal filler in mainland China, Hong Kong, Macau, and Taiwan.

Key Points: 
  • The technology comprises biomimetic, biocompatible, biodegradable materials engineered to look and feel like native soft tissue.
  • "We are excited to work with the team at Boyang Trading to bring Lumina to patients in Greater China.
  • Their long commercial history in aesthetics and complimentary portfolio of products provide a strong foundation for the launch of our breakthrough platform."
  • LifeSprout is targeting regulatory approvals for Lumina in the United States and European Union in 2025, and concurrently initiating additional clinical trial and registration plans with Boyang Trading for geographies in Greater China.

Longeveron Receives Notice of United States Patent Allowance for the Technology Behind its Lead Investigation Product Lomecel-B™

Retrieved on: 
Monday, January 29, 2024

The allowance impacts patients with Aging-related Frailty receiving vaccines for conditions such as Covid and the flu.

Key Points: 
  • The allowance impacts patients with Aging-related Frailty receiving vaccines for conditions such as Covid and the flu.
  • The new U.S. patent adds to the intellectual property from previous patents issued to Longeveron in the European Union and Japan.
  • Longeveron currently is conducting a trial of Aging-related Frailty in Japan aligned with the Japan Pharmaceuticals and Medical Devices Agency (PMDA).
  • Longeveron’s Patent Application 16/075,276 was titled Mesenchymal Stem Cells as Vaccine Adjuvants and Methods for Using the Same.